solute carrier family 20 member 1 pseudogene 2Genealiases: []
Q-omics provides the consensus-scored SLC20A1P2 profile across patient tissues and cancer cell-line models. SLC20A1P2 expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, SLC20A1P2 is differentially expressed in 5, with the highest sampling consensus in LUSC. Additionally, SLC20A1P2 RNA expression shows 6,854 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRP, LUSC, and THYM as cancer lineages where SLC20A1P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC20A1P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC20A1P2 survival associations across molecular data types. SLC20A1P2 RNA expression shows survival associations in the most cancer types (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC20A1P2 RNA expression–survival associations across cancer types. High SLC20A1P2 expression shows unfavorable associations in KIRP, DLBC and LUSC, but favorable associations in LUAD, THYM and HNSC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for SLC20A1P2 RNA expression.
This table summarizes SLC20A1P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for SLC20A1P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC20A1P2 shows lower tumor expression in LUSC, BRCA, UCEC, THCA and STAD. The LUSC box plot shows higher SLC20A1P2 RNA expression in normal versus tumor tissue (log2 FC = −0.062, t-test p < 0.001).
This table shows molecular features associated with SLC20A1P2 in patient tissues and cancer cell lines. In patient samples, SLC20A1P2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
